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Abstract 
Purpose: To investigate the effect of ursolic acid (UA)-incorporated glycol chitosan (GC) nanoparticles 
on inhibition of human osteosarcoma.  
Methods: U2OS and Saos-2 osteosarcoma cells were transfected with ursolic acid (UA) incorporated 
glycol chitosan (GC) nanoparticles. Ultraviolet (UV) spectrophotometry was used to measure drug 
contents in nanoparticles at 365 nm with empty GC vehicles as blank. Bicinchoninic acid assay (BCA) 
method was employed to determine protein concentration. Identification of apoptosis and necrosis in 
osteosarcoma cells was performed by propidium iodide and FITC-annexin V reagents, respectively. 
FAC Scan flow cytometry was used to analyse apoptotic cells.  
Results: Among the range of UA concentrations tested, the minimum effective concentration was 10 
µM with half inhibitory concentration IC50 of 25 µM. In U2OS cells, treatment with 10 and 25 µM UA-
induced apoptosis in 5.89 ± 3.90 and 60.54 ± 5.40 % cells, respectively, compared to 2.05 ± 1.01 % 
cells for control. In Saos-2 cells, exposure to 10 and 25 µM UA induced apoptosis in 9.86 ± 8.89 and 
47.54 ± 14.5 % cells, respectively, compared to 1.79 ± 0.23 % for control cells. Western blot analysis 
revealed translocation of Bax and Bcl-2 proteins from mitochondria to cell cytosol. Increase in UA 
concentration from 10 µM to 25 µM led to increase in the proportion of cells in G0/G1 phase and 
decrease in the number of cells in S and G2/M phases. These results confirm that UA transfection 
arrests cell cycle in G0/G1 phase in human osteosarcoma cell lines. 
Conclusion: UA transfection resulted in the inhibition of cell proliferation, Ezh2 expression inhibition, 
and apoptosis via mitochondrial pathway due to decrease in membrane potential and release of 
cytochrome C, as well as cell cycle arrest in G0/G1 phase. 
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Osteosarcoma, a common primary bone 
sarcoma has a 5-year survival rate of ~70 % in 
children and adolescents [1]. Patients with 
osteosarcoma have a poor prognosis, with 
overall survival rates of < 20 % [1]. 
Osteosarcoma is a well-defined clinical entity 
with a characteristic radiographic appearance, 
histologic features, a relatively consistent 
spectrum of clinical presentations, and 
established standard treatments. These features 
have been the subject of many prior book 
chapters and reviews [2-7]. However, all the 
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present treatments are less efficient. Therefore, 
the discovery of molecules with roles in the 
osteosarcoma inhibition is highly desired to 
improve the clinical treatment.  
 
Polycomb group genes (PcG) which are involved 
epigenetically in regulating gene transcription 
programs during development and cellular 
differentiation [8] harbor a catalytic subunit, 
Enhancer of Zeste homolog 2 (Ezh2). Knowledge 
regarding tumor stem cells has demonstrated 
that Ezh2 similarly controls expansion and 
differentiation of tumor initiating cells [9] and 
plays an important role in the development and 
progression of cancer [10,11]. Myelodysplastic 
syndromes involving inhibition mutations in Ezh2 
gene proves that Ezh2 functions as a tumor 
suppressor [12,13]. Ezh2 inhibits cell 
differentiation to maintain stemness of tumor 
cells [14,15]. 
 
Triterpenes and their derivatives have been 
reported to possess activities such as anti-HIV 
[16-19], inhibition of HIV protease [20] and 
cytotoxicity to tumor cell lines [21,22]. Ursolic 
acid (Fig 1), a pentacyclic triterpene isolated in 
abundance from the peels of Malus pumila Mill 
has been reported to possess a wide range of 
pharmacological properties, including anti-
inflammatory, antiallergic, antibacterial, antiviral, 
antitumor and cytotoxic activities being the most 
intriguing. Owing to its biological potential, it was 
ranked as one of the most promising 
tumorpreventive medications by Japanese 
researchers [17]. Mechanistic studies revealed 
that ursolic acid blocks the cell cycle progression 
in G1 phase and its treatment results in the 
triggering of apoptosis as determined by DNA 
fragmentation assay. Despite its in vitro 
biological promise, its poor bioavailability under 
in vivo restricts its clinical applications. One of 
the techniques to improve the bioavailability of 
this molecule is the development of polymeric 
micelles, like glycol chitosan micelle. In the 
present study effect of UA-incorporated glycol 





Cell culture  
 
Human osteosarcoma cell lines, U2OS and 
Saos-2 were purchased from the Health Science 
Research Resources Bank (Osaka, Japan). The 
cells were maintained in RPMI 1640 medium 
(RPMI: ECM = 4:1) supplemented with 10 % fetal 
bovine serum at 37 oC in 5 % CO2 in a humidified 
atmosphere. 
 
Chemicals and reagents  
 
Glycol chitosan (GC), ursolic acid (UA), dialysis 
membranes (MWCO = 12,000 g/mol) and 
propidium iodide (PI) were purchased from 




Fig 1: Structure of ursolic acid (UA) and glycol chitosan (GC) 
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FITC-annexin V was obtained from Santa Cruz, 
CA, 95060, USA. This study was approved by 
the Institutional Review Board and Ethics 
Committee of the Nanjing University, Jiangsu, 
China. 
 
Preparation of UA-incorporated GC 
nanoparticles  
 
The UA-incorporated GC nanoparticles were 
prepared by adding a solution containing 5 mg 
UA in 1 mL of DMF to an aqueous solution 
containing 40 mg of GC in 10 mL of de-ionized 
water. The solution was stirred for 20 min at 
room temperature in a dark room. A dialysis 
membrane was used to prepare dialyzed solution 
against deionized water by dialysis for 1 day. Out 
of 20 mL prepared by adding deionized water to 
the dialyzed solution, 100 µL was diluted with 9.9 
mL of DMSO. The absorbance was measured at 
365 nm using UV spectrophotometer (UV-1200, 
Shimadzu Co. Ltd., Kyoto, Japan) and compared 
with empty GC vehicles used as blank.  
 
Cell proliferation inhibition assay (MTT assay)  
 
In each well of a 96-well plate, aliquots 
containing 2.5 × 105 cells were seeded. The cells 
were incubated overnight in a 5 % CO2 incubator 
at 37 oC and then UA-incorporated GC 
nanoparticle solution was added to each well. 
After dilution with RIMI 1640 (10 % FBS), these 
were used to treat the tumor cells. RIMI 1640 (10 
% FBS) with 0.1 % (v/v) DMSO was used as 
control. Incubation for 48 h at 37 oC was followed 
by addition of 25 µL of MTT (3 mg/mL in PBS) to 
each well and incubation was continued for 4 h. 
To each well was added 100 µL of SDS–HCl 
solution (SDS 10 % w/v, 0.01 M HCl) and 
incubated again for 12 h. An Infinite M200 pro 
reader (Tecan Austria GmbH, Salzburg, Austria) 
was used to measure the absorbance at 570 nm. 
The viable cells were expressed as percentage 
of control and all the experiments were 




The UA-GC nanoparticle treated osteosarcoma 
cells were washed twice in PBS followed by 
addition of Lysis buffer (50 mM Tris-HCl pH 7.4, 
containing 137 mM NaCl, 10 % glycerol, 100 mM 
sodium vanadate, 1 mM PMSF, 10 mg/ml 
aprotinin, 10 mg/ml leupeptin, 1 % NP-40, and 5 
mM cocktail). Bicinchoninic acid assay (BCA) 
method was used to determine protein 
concentration. Equal amounts of protein were 
loaded and resolved by electrophoresis on a 10 
% polyacrylamide gel. The semi-dry method was 
used to transfer proteins onto a PVDF membrane 
which was then blocked with 5 % non-fat dry milk 
overnight. After TBST washing, the membrane 
was incubated for 2 h with primary antibodies 
and then washed again with TBST before 
incubation with secondary antibodies for 2 h. The 
x-ray autoradiography was performed and the 
gray scale images analysed using BioImaging 
System (UVP, USA). 
 
Flow cytometric analysis  
 
Identification of apoptosis and necrosis in 
osteosarcoma cells was carried out using 
propidium iodide and FITC-annexin V reagents 
respectively. Treatment of cells with various 
concentrations of UA-incorporated GC 
nanoparticles for 24 h was followed by washing 
with PBS. After suspension in binding buffer (10 
mM HEPES pH 7.4) containing 150 mM NaCl, 5 
mM KCl, 1 mM MgCl2, and 1.8 mM CaCl2) and 
FITC annexin V (1 µg/mL), the pellets were 
incubated for 20 min. PI (10 µg/mL) was added 
to stain necrotic cells under dark conditions and 
incubation was continued for 10 min more. FAC 
Scan flow cytometer (Becton Dickenson 
Biosciences, San Jose, CA, USA) was used to 
analyse the cells.  
 
Detection of single-strand DNA (ssDNA)  
 
In a 96-multiwell plate, 10000 cells/well were 
seeded and incubated with the UA-incorporated 
GC nanoparticles. The cells were then fixed with 
80 % methanol for 30 min. The plates were dried 
and incubated with formaldehyde for 10 min at 
room temperature followed by 10 min at 75 °C, 
and then at 4 °C for 5 min. With 3 % non-fat dry 
milk cells were incubated for 1 h followed by 
incubation with the antibody mixture (containing 
a primary monoclonal antibody to ssDNA and 
horseradish peroxidase-labeled secondary 
antibody) for 30 min. The addition of 2-2’-azino-
bis[3-ethylbenziazoline-6-sulfonic acid] solution 
permitted the reading of the plates at 405 nm in a 
standard microtiter reader. The ssDNA and 
necrotic cells obtained by hyperthermia were 





Statistical analysis was performed using 
Student's t-test with the aid of SPSS 16.0 
statistical software, and the differences were 
considered statistically significant at p < 0.05. 
Data are presented as mean ± standard (SD). 
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Inhibition of proliferation of human 
osteosarcoma cells  
 
The results from MTT assay revealed a dose-
dependent inhibition of the U2OS and Saos-2 
cell proliferation on UA treatment after 24 h. 
Among the range of concentrations (5 to 50 µM) 
tested, the inhibition was significant at 10 µM 
with a reduction in O.D. values of 16 ± 0.6 and 
13 ± 0.8 % for U2OS and Saos-2 cell lines 
respectively. The reductions in absorbance for 
20, 30 and 40 µM were 23 ± 2, 63 ± 3.5, 90 ± 10 
% for Saos-2 and 36 ± 3.2, 64 ± 3.43 and 89 ± 
10.34 % for Saos-2 cells respectively. The IC50 
values of UA were 24.2 ± 2.8 µM for U2OS cells 
and 23.9.1 ± 2.16 µM for Saos-2. 
 
Daily MTT data using 25 µM UA for 4 days show 
that growth inhibition of both the cell lines was 
maximum on day 4 (Fig. 2A,B). 
 
Inhibition of Ezh2 expression in human 
osteosarcoma cells  
 
The results showed a significant decrease in 
Ezh2 expression level after 24 h of UA-
incorporated GC nanoparticles (25 µM) 
transfection compared to control. The Ezh2 
inhibition by UA lasted for at least 72 h after the 
UA-incorporated GC nanoparticle transfection 
(Fig. 3). These results suggest that after the 
transfection of the UA at 25 µM for 24 h, the 










Fig. 3: Expression of Ezh2 and protein in U2OS and Saos-2 cells after UA transfection. (A and C) After the U2OS 
and Saos-2 cells were transfected with 25 µM UA, the expression level of the Ezh2 and proteins was significantly 
reduced. (B) The efficacy of UA to inhibit the Ezh2 expression was further analysed by western blotting analysis 
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Induction of apoptosis in U2OS and Saos-2 
human osteosarcoma cells  
 
In U2OS cells treatment with 10 and 25 µM UA 
induced apoptosis in 5.89 ± 3.9 and 60.54 ± 5.4 
% cells respectively compared to 2.05 ± 1.01 % 
cells in control (Fig. 4). Similar results were 
observed in Saos-2 cells, where in exposure to 
10 and 25 µM UA induced apoptosis in 9.86 ± 
8.89 and 47.54 ± 14.5 % cells, respectively, 
compared to  1.79 ± 0.23 % in control cells (data 
not shown). 
 
Induction of apoptosis in the U2OS and Saos-
2 human osteosarcoma cells  
 
The results clearly showed that increasing in 
concentration of UA in UA-incorporated GC 
nanoparticle from 10 to 25 µM significantly 
reduced the mitochondrial membrane potential in 
U2OS cells (Fig 5A). Western blot analysis 
revealed translocation of Bax and Bcl-2 proteins 
from mitochondria to cell cytosol (Fig 5B). Similar 
results were obtained in Saos-2 human 
osteosarcoma cell lines. 
 
Cell cycle arrest in the G0/G1 phase in U2OS 
and Saos-2 human osteosarcoma cells  
 
The results from flow cytometry showed a 
significant increase in G0/G1 cell population in 
both U2OS and Saos-2 cells with subsequent 
decrease in S and G2/M phase on treatment with 
UA (10 µM) (Fig 6B, D). The increase in 
concentration of UA from 10 µM to 25 µM led to 
further increase in the percentage of cells in 
G0/G1 phase and subsequent decrease in cell 
percentage from S and G2/M phase (Fig. 6C, E). 
These results confirm that UA transfection 
arrests cell cycle in G0/G1 phase in human 




UA-incorporated GC nanoparticles formed by 
electrostatic interaction between –COOH group 
of UA and –NH2 group of glycol chitosan were 
prepared. The presence of reactive –NH2 group 
makes chitosan a suitable substrate for drug 
conjugation and ion complex formation with 
anionic drugs [10]. Thünemann and Beyermann 
initially developed the concept of nanoparticle 
formation between acid and positively charged 
macromolecules [23]. The present study 
demonstrates the effect of UA-incorporated GC 
nanoparticles on inhibition of osteosarcoma cell 







Fig 4: UA-induced apoptosis in U2OS cells. Cultures 
were grown either in medium containing empty GC 
vesicles (control) or in a medium containing 10 µM or 
25µM UA. The arrows indicate apoptotic cells; 
magnified image of cells was shown in corner
Control 
10 µM UA 
20 µM UA 
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Fig 5: UA induces apoptosis in U2OS cells through the mitochondrial pathway (A) Changes in the mitochondrial 
membrane potential were analysed by JC-1 staining and subsequent flow cytometry. (B) The expression levels of 




Fig 6: Effect of UA transfection on cell cycle arrest in U2OS and Saos-2 cells.  (A) The cell cycle distribution of 
U2OS and Saos-2 cells that had been treated with empty GC vesicles. (B, C, D and E) The cell cycle distribution 
of U2OS and Saos-2 cells that had been treated with 10 and 25µM UA incorporated GC nanoparticles 
 
showed a marked inhibition in cell proliferation on 
treatment with UA-incorporated GC nanoparticles 
after 24 h. The proliferation inhibition continued 
for 72 h and the effect was seen to be maximum 
on day 4. 
 
It has been shown that polycomb group genes 
are epigenetically associated with the regulation 
of gene transcription programs during cellular 
differentiation and development [8]. Ezh2 
controls expansion and differentiation of tumor 
initiating cells and plays an important role in the 
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development and progression of cancer [9-11]. 
The results from the present study revealed that 
UA transfection in U2OS and Saos-2 human 
osteosarcoma cells caused inhibition of Ezh2 
expression.  
 
The results from apoptosis and necrosis assay 
showed increase in the percentage of apoptosis 
on increasing the   concentration of UA. It was 
observed that osteosarcoma cells undergo 
apoptosis through mitochondrial pathway. The 
Bax and Bcl-2 proteins were seen to translocate 
from mitochondria into cytoplasm where they led 
to release of cytochrome c. Cytochrome c then 
activates caspase 9 and caspase 3, which play 
key roles in the apoptosis pathway. The increase 
in concentration of UA in UA-incorporated GC 
nanoparticle from 10 µM to 25 µM significantly 
reduced the mitochondrial membrane potential in 
U2OS cells. Therefore, these results suggest that 
the UA inhibition of Ezh2 expression induces 
apoptosis through the mitochondrial pathway in 
human osteosarcoma cells.  Our results from 
flow cytometry also suggest that UA induces cell 




UA induces proliferation inhibition, apoptosis and 
cell cycle arrest in G0/G1 in osteosarcoma cells 
via inhibition of Ezh2 expression. Thus, UA-
incorporated GC nanoparticles may be a 
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